Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Pravastatin
Drug ID BADD_D01824
Description Pravastatin is the 6-alpha-hydroxy acid form of [mevastatin].[T303] Pravastatin was firstly approved in 1991 becoming the second available statin in the United States. It was the first statin administered as the active form and not as a prodrug.[T274] This drug was developed by Sankyo Co. Ltd.; however, the first approved pravastatin product was developed by Bristol Myers Squibb and FDA approved in 1991.[L6142] Pravastatin is made through a fermentation process in which [mevastatin] is first obtained. The manufacturing process is followed by the hydrolysis of the lactone group and the biological hydroxylation with _Streptomyces carbophilus_ to introduce the allylic 6-alcohol group.[T239]
Indications and Usage For the treatment of hypercholesterolemia and to reduce the risk of cardiovascular disease.
Marketing Status Prescription; Discontinued
ATC Code C10AA03
DrugBank ID DB00175
KEGG ID D08410
MeSH ID D017035
PubChem ID 54687
TTD Drug ID D02RQU
NDC Product Code Not Available
Synonyms Pravastatin | Eptastatin | Vasten | CS-514 | CS 514 | CS514 | Lin-Pravastatin | Lin Pravastatin | Lipemol | Liplat | Nu-Pravastatin | Nu Pravastatin | Prareduct | Mevalotin | Pravachol | Elisor | Selektine | Lipostat | Pravacol | Pravasin | Pravastatin Monosodium Salt, (6 beta)-Isomer | Pravastatin Sodium | Pravastatin Sodium Salt | Sodium Salt, Pravastatin | Pravastatin tert-Octylamine Salt | Pravastatin tert Octylamine Salt | Pravastatin, (6 beta)-Isomer | RMS-431 | RMS 431 | RMS431 | SQ-31000 | SQ 31000 | SQ31000 | SQ-31,000 | SQ 31,000 | SQ31,000 | Apo-Pravastatin | Apo Pravastatin | Bristacol
Chemical Information
Molecular Formula C23H36O7
CAS Registry Number 81093-37-0
SMILES CCC(C)C(=O)OC1CC(C=C2C1C(C(C=C2)C)CCC(CC(CC(=O)O)O)O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Acute myocardial infarctionStromelysin-1P08254T8670210190398; 12485468; 16323393; 9420339
Angina pectorisStromelysin-1P08254T8670210190398; 12485468; 16323393; 9420339
AngioplastyStromelysin-1P08254T8670210190398; 12485468; 16323393; 9420339
ArteriosclerosisLiver carboxylesterase 1P23141T763699420339; 14660992; 14998629; 14984434
Cerebrovascular accidentStromelysin-1P08254T8670210190398; 12485468; 16323393; 9420339
DeathStromelysin-1P08254T8670210190398; 12485468; 16323393; 9420339
Myocardial ischaemiaApolipoprotein EP02649T2168910736278; 7605354
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Lenticular opacities06.06.01.003--Not Available
Leukopenia01.02.02.001--Not Available
Liver disorder09.01.08.001--Not Available
Liver function test abnormal13.03.01.013--Not Available
Loss of consciousness17.02.04.0040.000072%Not Available
Loss of libido19.08.03.003--Not Available
Malaise08.01.01.003--
Memory impairment19.20.01.003; 17.03.02.0030.000072%
Menopausal symptoms21.02.02.002--Not Available
Mood swings19.04.03.001--Not Available
Muscle rupture12.01.07.010; 15.05.07.0030.000109%Not Available
Muscle spasms15.05.03.0040.000290%
Muscular weakness17.05.03.005; 15.05.06.0010.000145%
Musculoskeletal pain15.03.04.007--
Myalgia15.05.02.0010.001376%
Myasthenia gravis17.05.04.001; 15.05.08.001; 10.04.05.0010.000072%
Myocardial infarction24.04.04.009; 02.02.02.007--
Myoglobinuria02.04.02.006; 20.02.01.010; 15.05.03.009--Not Available
Myoglobin urine present13.16.02.002--Not Available
Myopathy15.05.05.0010.000253%Not Available
Myxoedema23.07.04.007; 05.02.03.0020.000072%Not Available
Nasopharyngitis22.07.03.002; 11.01.13.002--Not Available
Nausea07.01.07.001--
Nervousness19.06.02.003--Not Available
Neuropathy peripheral17.09.03.003--Not Available
Nightmare19.02.03.003--Not Available
Nocturia20.02.03.001--Not Available
Oedema14.05.06.010; 08.01.07.006--Not Available
Ophthalmoplegia17.17.02.005; 06.05.02.003--Not Available
Pain08.01.08.004--
The 4th Page    First    Pre   4 5 6 7    Next   Last    Total 7 Pages